MOG and myeloid sarcoma: Thus, in “complex EAE”, a murine model that better resembles the complex pathogenic anti-myelin autoimmunity in MS, immune-specific treatment that targets pathogenic T cells reactive against only a single MOG or PLP epitope (peptide) is significantly less effective than treatment with a “multi-epitope targeting” agent that can concomitantly neutralize multiple pathogenic autoimmune T cells reactive against multiple myelin antigens/epitopes.